Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Alphala Corp. Enters Into Letter Of Intent With FV Pharma Inc.

By Pharmaceutical Processing | June 17, 2014

TORONTO – Alphala Corp. (OTCBB:ALPC) is pleased to announce that it has entered into a Letter of Intent with FV Pharma Inc., a private Ontario, Canada corporation (“FV Pharma”), and certain shareholders of FV Pharma, to purchase all the Class B non-voting shares of FV Pharma. FV Pharma is striving to establish a state of the art medical marijuana production facility located in Cobourg, Ontario, one (1) hour east of Toronto.

FV Pharma has applied to Health Canada to become a licensed commercial producer of marijuana under the Government of Canada’s new Marijuana for Medical Purposes Regulations (the “MMPR”). The company’s application is in the personal security checks stage of the process, and an in-depth review verification of the application must still occur before Health Canada conducts a pre-license inspection of its proposed facility. If successful, FV Pharma will receive a license to produce marijuana for medical purposes. FV Pharma is one of many companies seeking to start producing marijuana on a commercial scale under the MMPR, which became effective on April 1, 2014.

The Letter of Intent states that the Company will issue an aggregate of:

150,000,000 shares of its common stock to the holders of FV Pharma’s Class B shares upon the closing of the transaction, which is expected to take the form of a share exchange. The completion of the transaction is subject to standard due diligence by both sides and the successful negotiation of a definitive agreement.

The company will release additional information regarding the status of FV Pharma’s application under the MMPR promptly upon the receipt of any such information from Health Canada.

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE